Leerink Partners analyst David Risinger maintained a Hold rating on Amgen (AMGN – Research Report) yesterday and set a price target of $305.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
David Risinger’s rating is based on Amgen’s recent financial performance and future guidance. The company reported fourth-quarter results that surpassed market expectations, with revenue and earnings per share (EPS) both exceeding consensus estimates. Despite this strong performance, the guidance for 2025 remains fairly aligned with market expectations, which has led to a Hold rating.
Furthermore, while Amgen’s key growth drivers, such as Repatha and EVENITY, showed impressive sales growth, Risinger has noted that there are still significant challenges, particularly in market penetration for EVENITY. This indicates potential growth opportunities but also highlights existing hurdles. The company’s long-term revenue and EPS growth projections have been slightly adjusted, yet these updates do not significantly alter the overall outlook, justifying the Hold stance.
In another report released yesterday, Truist Financial also maintained a Hold rating on the stock with a $298.00 price target.
AMGN’s price has also changed slightly for the past six months – from $325.220 to $307.810, which is a -5.35% drop .